ATRC logo

ATRC
Atricure Inc

391
Mkt Cap
$1.35B
Volume
160.00
52W High
$43.18
52W Low
$25.52
PE Ratio
-275.54
ATRC Fundamentals
Price
$26.59
Prev Close
$26.69
Open
$26.43
50D MA
$28.80
Beta
1.01
Avg. Volume
735,513.89
EPS (Annual)
-$0.2398
P/B
2.74
Rev/Employee
$395,946.67
$1,798.06
Loading...
Loading...
News
all
press releases
AtriCure (ATRC) Q1 2026 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·8d ago
News Placeholder
More News
News Placeholder
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q1 Earnings
Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·9d ago
News Placeholder
AtriCure (NASDAQ:ATRC) Releases FY 2026 Earnings Guidance
AtriCure (NASDAQ:ATRC) updated its FY 2026 earnings guidance. The company provided EPS guidance of 0.000-0.040 for the period, compared to the consensus estimate of 0.130. The company also issued revenue guidance of $600.0 millionillion-$610.0 millionillion, compared to the consensus estimate of...
MarketBeat·9d ago
News Placeholder
AtriCure Q1 Earnings Call Highlights
AtriCure (NASDAQ:ATRC) reported first-quarter 2026 results that management described as an accelerated growth start to the year, highlighted by double-digit revenue gains and improved profitability...
MarketBeat·9d ago
News Placeholder
AtriCure (ATRC) Reports Break-Even Earnings for Q1
AtriCure (ATRC) delivered earnings and revenue surprises of +100.00% and +1.43%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·9d ago
News Placeholder
AtriCure Reports First Quarter 2026 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management...
Business Wire·9d ago
News Placeholder
AtriCure (NASDAQ:ATRC) Reaches New 52-Week Low - What's Next?
AtriCure (NASDAQ:ATRC) Sets New 52-Week Low - What's Next...
MarketBeat·15d ago
News Placeholder
AtriCure, Inc. (NASDAQ:ATRC) Given Average Rating of "Moderate Buy" by Analysts
Shares of AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eleven analysts that are currently covering the firm, MarketBeat.com...
MarketBeat·15d ago
News Placeholder
AtriCure (ATRC) Projected to Post Quarterly Earnings on Tuesday
AtriCure (NASDAQ:ATRC) will be releasing its Q1 2026 earnings after the market closes on Tuesday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-5-atricure-inc-stock...
MarketBeat·16d ago
News Placeholder
AtriCure to Participate in the 2026 Bank of America Securities Health Care Conference
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management...
Business Wire·16d ago
<
1
2
...
>

Latest ATRC News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.